Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26033801

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2015 Jul 10
First author
Bielack SS

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2016 Nov 20;34(33):4059. doi: 10.1200/JCO.2016.70.9923.
    note
    Source null
    related pmid
    29236598
    relationship
    Erratum in

Authors and identifiers

  1. name
    Bielack SS
    type
    Author
  2. name
    Smeland S
    type
    Author
  3. name
    Whelan JS
    type
    Author
  4. name
    Marina N
    type
    Author
  5. name
    Jovic G
    type
    Author
  6. name
    Hook JM
    type
    Author
  7. name
    Krailo MD
    type
    Author
  8. name
    Gebhardt M
    type
    Author
  9. name
    Pápai Z
    type
    Author
  10. name
    Meyer J
    type
    Author
  11. name
    Nadel H
    type
    Author
  12. name
    Randall RL
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bielack SS
    type
    Author
  2. name
    Smeland S
    type
    Author
  3. name
    Whelan JS
    type
    Author
  4. name
    Marina N
    type
    Author
  5. name
    Jovic G
    type
    Author
  6. name
    Hook JM
    type
    Author
  7. name
    Krailo MD
    type
    Author
  8. name
    Gebhardt M
    type
    Author
  9. name
    Pápai Z
    type
    Author
  10. name
    Meyer J
    type
    Author
  11. name
    Nadel H
    type
    Author
  12. name
    Randall RL
    type
    Author
bibliography ids
  1. nci-bib-8dca266daeca192f76c904d0
book metadata
content sha256
0498b7b25291d6ad6b9111c73c5ecb398bbe5b0472feb6cea64619c267045f27
document type
citation
dois
  1. 10.1200/JCO.2014.60.0734
electronic publication date
display
2015 Jun 1
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:26033801
immutable id
pubmed:26033801@0498b7b25291d6ad6b9111c73c5ecb398bbe5b0472feb6cea64619c267045f27
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
20
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
2279-87
volume
33
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2016 Nov 20;34(33):4059. doi: 10.1200/JCO.2016.70.9923.
    note
    Source null
    related pmid
    29236598
    relationship
    Erratum in
outcomes validated
false
pmid
26033801
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
2d5c6355482f9bc4a45eb58030060d757df5ef1af32715001fff425d0b565c85
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 Jul 10
precision
day
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26033801/
title
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.

Preserved source evidence · Not medical advice